Human basophil/mast cell releasability: IX. Heterogeneity of the effects of opioids on mediator release

C. Stellato, R. Cirillo, A. De Paulis, V. Casolaro, V. Patella, P. Mastronardi, B. Mazzarella, G. Marone

Research output: Contribution to journalArticle

Abstract

Opioids differ in their capacity to cause release of histamine. The effects of increasing concentrations of three opioids (morphine, buprenorphine, and fentanyl) were studied on the release of preformed (histamine and tryptase) and de novo synthesized (prostaglandin D2 [PGD2] and peptide-leukotriene C4 [LTC4]) chemical mediators from human peripheral blood basophils and mast cells isolated from skin tissues or lung parenchyma. Basophils released <5% of their histamine content and did not synthesize significant amounts of LTC4 when incubated with any of the opioids. Mast cells showed markedly different responses to the three opioids. Morphine (10-5-3 x 10-4 M), in a concentration-dependent manner, induced histamine and tryptase release from skin but not from lung mast cells, up to a maximum of 18.2 ± 1.9% and 13.0 ± 4.1 μg/107 cells, respectively. Morphine did not induced de novo synthesis of PGD2 from skin mast cells. Buprenorphine (10-6-10-4 M), in a concentration-dependent manner, caused histamine and tryptase release from lung but not from skin mast cells, to a maximum of 47.6 ± 7.2% and 35.1 ± 13.6 μg/107 cells, respectively. Buprenorphine also induced de novo synthesis of PGD2 and LTC4 from lung mast cells. Fentanyl (10-5-10-3 M) did not induce histamine and tryptase release or the de novo synthesis of PGD2 or LTC4 from any mast cells. Histamine release caused by buprenorphine from lung mast cells was slow (t 1/2 = 11.2 ± 3.6 min) compared with that induced by morphine from skin mast cells (t 1/2 <1 min, P <0.001). The releasing activity of buprenorphine on lung mast cells was abolished by lowering the temperature of the incubation buffer to 22° C and 4° C. Buprenorphine's capacity to induce histamine release from lung mast cells was partially dependent on extracellular Ca2+ and was not reduced by metabolic impairment caused by preincubation (15-40 min) with 2-deoxy-D- glucose plus antimycin A. Thus, there appear to be functional differences between human basophils and mast cells and between mast cells from different anatomic sites in response to the three opioids tested.

Original languageEnglish (US)
Pages (from-to)932-940
Number of pages9
JournalAnesthesiology
Volume77
Issue number5
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Basophils
Mast Cells
Opioid Analgesics
Histamine Release
Buprenorphine
Prostaglandin D2
Tryptases
Leukotriene C4
Lung
Morphine
Skin
Fentanyl
Antimycin A
Deoxyglucose
Histamine
Blood Cells
Buffers

Keywords

  • Analgesics, opioid: buprenorphine; fentanyl; morphine
  • Cells: basophils; mast cells
  • Enzymes: tryptase
  • Leukotriene C
  • Medication: histamine
  • Prostaglandin D

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Stellato, C., Cirillo, R., De Paulis, A., Casolaro, V., Patella, V., Mastronardi, P., ... Marone, G. (1992). Human basophil/mast cell releasability: IX. Heterogeneity of the effects of opioids on mediator release. Anesthesiology, 77(5), 932-940. https://doi.org/10.1097/00000542-199211000-00016

Human basophil/mast cell releasability : IX. Heterogeneity of the effects of opioids on mediator release. / Stellato, C.; Cirillo, R.; De Paulis, A.; Casolaro, V.; Patella, V.; Mastronardi, P.; Mazzarella, B.; Marone, G.

In: Anesthesiology, Vol. 77, No. 5, 1992, p. 932-940.

Research output: Contribution to journalArticle

Stellato, C, Cirillo, R, De Paulis, A, Casolaro, V, Patella, V, Mastronardi, P, Mazzarella, B & Marone, G 1992, 'Human basophil/mast cell releasability: IX. Heterogeneity of the effects of opioids on mediator release', Anesthesiology, vol. 77, no. 5, pp. 932-940. https://doi.org/10.1097/00000542-199211000-00016
Stellato, C. ; Cirillo, R. ; De Paulis, A. ; Casolaro, V. ; Patella, V. ; Mastronardi, P. ; Mazzarella, B. ; Marone, G. / Human basophil/mast cell releasability : IX. Heterogeneity of the effects of opioids on mediator release. In: Anesthesiology. 1992 ; Vol. 77, No. 5. pp. 932-940.
@article{a249f2eb066d44ecb7b0e28c0ff2892f,
title = "Human basophil/mast cell releasability: IX. Heterogeneity of the effects of opioids on mediator release",
abstract = "Opioids differ in their capacity to cause release of histamine. The effects of increasing concentrations of three opioids (morphine, buprenorphine, and fentanyl) were studied on the release of preformed (histamine and tryptase) and de novo synthesized (prostaglandin D2 [PGD2] and peptide-leukotriene C4 [LTC4]) chemical mediators from human peripheral blood basophils and mast cells isolated from skin tissues or lung parenchyma. Basophils released <5{\%} of their histamine content and did not synthesize significant amounts of LTC4 when incubated with any of the opioids. Mast cells showed markedly different responses to the three opioids. Morphine (10-5-3 x 10-4 M), in a concentration-dependent manner, induced histamine and tryptase release from skin but not from lung mast cells, up to a maximum of 18.2 ± 1.9{\%} and 13.0 ± 4.1 μg/107 cells, respectively. Morphine did not induced de novo synthesis of PGD2 from skin mast cells. Buprenorphine (10-6-10-4 M), in a concentration-dependent manner, caused histamine and tryptase release from lung but not from skin mast cells, to a maximum of 47.6 ± 7.2{\%} and 35.1 ± 13.6 μg/107 cells, respectively. Buprenorphine also induced de novo synthesis of PGD2 and LTC4 from lung mast cells. Fentanyl (10-5-10-3 M) did not induce histamine and tryptase release or the de novo synthesis of PGD2 or LTC4 from any mast cells. Histamine release caused by buprenorphine from lung mast cells was slow (t 1/2 = 11.2 ± 3.6 min) compared with that induced by morphine from skin mast cells (t 1/2 <1 min, P <0.001). The releasing activity of buprenorphine on lung mast cells was abolished by lowering the temperature of the incubation buffer to 22° C and 4° C. Buprenorphine's capacity to induce histamine release from lung mast cells was partially dependent on extracellular Ca2+ and was not reduced by metabolic impairment caused by preincubation (15-40 min) with 2-deoxy-D- glucose plus antimycin A. Thus, there appear to be functional differences between human basophils and mast cells and between mast cells from different anatomic sites in response to the three opioids tested.",
keywords = "Analgesics, opioid: buprenorphine; fentanyl; morphine, Cells: basophils; mast cells, Enzymes: tryptase, Leukotriene C, Medication: histamine, Prostaglandin D",
author = "C. Stellato and R. Cirillo and {De Paulis}, A. and V. Casolaro and V. Patella and P. Mastronardi and B. Mazzarella and G. Marone",
year = "1992",
doi = "10.1097/00000542-199211000-00016",
language = "English (US)",
volume = "77",
pages = "932--940",
journal = "Anesthesiology",
issn = "0003-3022",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Human basophil/mast cell releasability

T2 - IX. Heterogeneity of the effects of opioids on mediator release

AU - Stellato, C.

AU - Cirillo, R.

AU - De Paulis, A.

AU - Casolaro, V.

AU - Patella, V.

AU - Mastronardi, P.

AU - Mazzarella, B.

AU - Marone, G.

PY - 1992

Y1 - 1992

N2 - Opioids differ in their capacity to cause release of histamine. The effects of increasing concentrations of three opioids (morphine, buprenorphine, and fentanyl) were studied on the release of preformed (histamine and tryptase) and de novo synthesized (prostaglandin D2 [PGD2] and peptide-leukotriene C4 [LTC4]) chemical mediators from human peripheral blood basophils and mast cells isolated from skin tissues or lung parenchyma. Basophils released <5% of their histamine content and did not synthesize significant amounts of LTC4 when incubated with any of the opioids. Mast cells showed markedly different responses to the three opioids. Morphine (10-5-3 x 10-4 M), in a concentration-dependent manner, induced histamine and tryptase release from skin but not from lung mast cells, up to a maximum of 18.2 ± 1.9% and 13.0 ± 4.1 μg/107 cells, respectively. Morphine did not induced de novo synthesis of PGD2 from skin mast cells. Buprenorphine (10-6-10-4 M), in a concentration-dependent manner, caused histamine and tryptase release from lung but not from skin mast cells, to a maximum of 47.6 ± 7.2% and 35.1 ± 13.6 μg/107 cells, respectively. Buprenorphine also induced de novo synthesis of PGD2 and LTC4 from lung mast cells. Fentanyl (10-5-10-3 M) did not induce histamine and tryptase release or the de novo synthesis of PGD2 or LTC4 from any mast cells. Histamine release caused by buprenorphine from lung mast cells was slow (t 1/2 = 11.2 ± 3.6 min) compared with that induced by morphine from skin mast cells (t 1/2 <1 min, P <0.001). The releasing activity of buprenorphine on lung mast cells was abolished by lowering the temperature of the incubation buffer to 22° C and 4° C. Buprenorphine's capacity to induce histamine release from lung mast cells was partially dependent on extracellular Ca2+ and was not reduced by metabolic impairment caused by preincubation (15-40 min) with 2-deoxy-D- glucose plus antimycin A. Thus, there appear to be functional differences between human basophils and mast cells and between mast cells from different anatomic sites in response to the three opioids tested.

AB - Opioids differ in their capacity to cause release of histamine. The effects of increasing concentrations of three opioids (morphine, buprenorphine, and fentanyl) were studied on the release of preformed (histamine and tryptase) and de novo synthesized (prostaglandin D2 [PGD2] and peptide-leukotriene C4 [LTC4]) chemical mediators from human peripheral blood basophils and mast cells isolated from skin tissues or lung parenchyma. Basophils released <5% of their histamine content and did not synthesize significant amounts of LTC4 when incubated with any of the opioids. Mast cells showed markedly different responses to the three opioids. Morphine (10-5-3 x 10-4 M), in a concentration-dependent manner, induced histamine and tryptase release from skin but not from lung mast cells, up to a maximum of 18.2 ± 1.9% and 13.0 ± 4.1 μg/107 cells, respectively. Morphine did not induced de novo synthesis of PGD2 from skin mast cells. Buprenorphine (10-6-10-4 M), in a concentration-dependent manner, caused histamine and tryptase release from lung but not from skin mast cells, to a maximum of 47.6 ± 7.2% and 35.1 ± 13.6 μg/107 cells, respectively. Buprenorphine also induced de novo synthesis of PGD2 and LTC4 from lung mast cells. Fentanyl (10-5-10-3 M) did not induce histamine and tryptase release or the de novo synthesis of PGD2 or LTC4 from any mast cells. Histamine release caused by buprenorphine from lung mast cells was slow (t 1/2 = 11.2 ± 3.6 min) compared with that induced by morphine from skin mast cells (t 1/2 <1 min, P <0.001). The releasing activity of buprenorphine on lung mast cells was abolished by lowering the temperature of the incubation buffer to 22° C and 4° C. Buprenorphine's capacity to induce histamine release from lung mast cells was partially dependent on extracellular Ca2+ and was not reduced by metabolic impairment caused by preincubation (15-40 min) with 2-deoxy-D- glucose plus antimycin A. Thus, there appear to be functional differences between human basophils and mast cells and between mast cells from different anatomic sites in response to the three opioids tested.

KW - Analgesics, opioid: buprenorphine; fentanyl; morphine

KW - Cells: basophils; mast cells

KW - Enzymes: tryptase

KW - Leukotriene C

KW - Medication: histamine

KW - Prostaglandin D

UR - http://www.scopus.com/inward/record.url?scp=0026453466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026453466&partnerID=8YFLogxK

U2 - 10.1097/00000542-199211000-00016

DO - 10.1097/00000542-199211000-00016

M3 - Article

C2 - 1280014

AN - SCOPUS:0026453466

VL - 77

SP - 932

EP - 940

JO - Anesthesiology

JF - Anesthesiology

SN - 0003-3022

IS - 5

ER -